ZSAN - Zosano Pharma granted patent related to migraine treatment M207

Zosano Pharma (ZSAN) announced that it has been granted an additional patent covering method of use of M207 for the acute treatment of migraine.The patent covers methods for the release of active drug from Zosano’s microneedle system in about one minute and reaching potentially therapeutic levels as quickly as 30 minutes upon application.Zosano’s M207 patent portfolio now includes two U.S. patents with claims covering composition of matter and method of use for M207 with expirations in 2037.Shares up nearly 6% premarket.

For further details see:

Zosano Pharma granted patent related to migraine treatment M207